"Li-Fraumeni Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Rare autosomal dominant syndrome characterized by mesenchymal and epithelial neoplasms at multiple sites. MUTATION of the p53 tumor suppressor gene, a component of the DNA DAMAGE response pathway, apparently predisposes family members who inherit it to develop certain cancers. The spectrum of cancers in the syndrome was shown to include, in addition to BREAST CANCER and soft tissue sarcomas (SARCOMA); BRAIN TUMORS; OSTEOSARCOMA; LEUKEMIA; and ADRENOCORTICAL CARCINOMA.
| Descriptor ID |
D016864
|
| MeSH Number(s) |
C04.700.600 C16.320.700.600 C18.452.284.520
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Li-Fraumeni Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Li-Fraumeni Syndrome".
This graph shows the total number of publications written about "Li-Fraumeni Syndrome" by people in this website by year, and whether "Li-Fraumeni Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 1 | 4 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 8 | 0 | 8 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 1 | 4 |
| 2020 | 7 | 0 | 7 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 2 | 0 | 2 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Li-Fraumeni Syndrome" by people in Profiles.
-
TP53-associated early breast cancer: new observations from a large cohort. J Natl Cancer Inst. 2024 Aug 01; 116(8):1246-1254.
-
Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol. 2024 Jun 20; 42(18):2186-2195.
-
Hematologic malignancies in Li-Fraumeni syndrome: A case report. Am J Med Genet A. 2024 07; 194(7):e63573.
-
Therapeutic Strategies for Gliomas Associated With Cancer Predisposition Syndromes. JCO Precis Oncol. 2024 Feb; 8:e2300442.
-
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations. JCO Clin Cancer Inform. 2024 Feb; 8:e2300167.
-
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discov. 2023 05 04; 13(5):1230-1249.
-
Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation. Nat Commun. 2023 03 27; 14(1):1694.
-
Clinical Applications and Controversies of Whole-Body MRI: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2023 04; 220(4):463-475.
-
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1621-1629.
-
Evolution of germline TP53 variant classification in children with cancer. Cancer Genet. 2022 06; 264-265:29-32.